Searched over 200M research papers for "dialysis binders"
10 papers analyzed
These studies suggest that phosphate binders, including sevelamer, lanthanum, and sucroferric oxyhydroxide, are effective in reducing serum phosphorus levels and mortality risk in chronic kidney disease and dialysis patients, though their cost-effectiveness and potential risks vary.
20 papers analyzed
Hyperphosphatemia is a common complication in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Phosphate binders are essential in managing serum phosphorus levels to prevent cardiovascular complications and improve patient outcomes. This article synthesizes recent research on the efficacy, safety, and cost-effectiveness of various phosphate binders used in dialysis patients.
Several studies have highlighted the efficacy of phosphate binders in reducing all-cause mortality among CKD patients. Sevelamer, a non-calcium-based binder, has been shown to significantly reduce the risk of all-cause mortality compared to calcium-containing binders . A randomized study involving nondialysis-dependent CKD patients found that those treated with sevelamer had lower all-cause mortality and a composite endpoint of death or dialysis inception compared to those treated with calcium carbonate. Additionally, a network meta-analysis of randomized controlled trials (RCTs) confirmed that sevelamer reduces the risk of all-cause mortality compared to calcium-based binders.
The safety profiles of phosphate binders vary significantly. Calcium-based binders, while effective, can lead to hypercalcemia and increased risk of vascular calcification . Sevelamer, on the other hand, is associated with fewer instances of hypercalcemia and has additional benefits such as reducing serum cholesterol levels and exerting anti-inflammatory effects . However, sevelamer can cause gastrointestinal adverse events, which are more frequent compared to calcium-based binders .
Iron-based binders like sucroferric oxyhydroxide have shown long-term efficacy in maintaining serum phosphorus levels with a lower pill burden compared to sevelamer, but they require monitoring for potential iron overload . Lanthanum carbonate is another effective binder that inhibits coronary artery calcium score (CACS) progression but lacks long-term safety data regarding tissue deposition .
The cost-effectiveness of phosphate binders is a critical consideration given the high costs associated with CKD management. A study evaluating the economic impact of sevelamer and lanthanum versus calcium-based binders found that sevelamer may be cost-effective before dialysis onset but not necessarily during dialysis. The study suggested that while sevelamer and lanthanum are effective, their higher costs compared to calcium-based binders may not justify their use in all patient populations.
Combining phosphate binders with different mechanisms of action can enhance efficacy while minimizing adverse effects. For instance, a trial involving the dual-mechanism treatment of tenapanor (an inhibitor of paracellular phosphate absorption) and phosphate binders showed significant reductions in serum phosphorus levels compared to binders alone. This approach may offer a promising strategy for better managing hyperphosphatemia in dialysis patients.
Phosphate binders play a crucial role in managing hyperphosphatemia in CKD patients undergoing dialysis. Sevelamer has demonstrated significant benefits in reducing mortality and managing serum phosphorus levels with a favorable safety profile compared to calcium-based binders. However, the higher costs associated with non-calcium binders like sevelamer and lanthanum necessitate careful consideration of their cost-effectiveness. Combining different phosphate binders may offer enhanced efficacy and safety, providing a tailored approach to individual patient needs. Further research is needed to confirm long-term outcomes and optimize treatment strategies for hyperphosphatemia in CKD patients.
Most relevant research papers on this topic